Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection
Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Ding Ding, Amy Hacker-Prietz, Jin He, Lei Zheng, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang
Radiat Oncol J. 2021;39(4):304-314. Published online 2021 Dec 17 DOI: https://doi.org/10.3857/roj.2021.00815
Citations to this article as recorded by 
The Current Role of Radiation in Pancreatic Cancer and Future Directions
Colin S. Hill, Joseph M. Herman
Clinical Colorectal Cancer.2023; 22(1): 12. CrossRef
Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?
F. Huguet, C. Cerbai, M.H. Ta, T. Sarrade, C. Evin, S. Aziez, E. Rivin del Campo, B. Durand, M. Loi
Cancer/Radiothérapie.2022; 26(6-7): 858. CrossRef
Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management
Ali Fawaz, Omar Abdel-Rahman
Cancer Management and Research.2022; Volume 14: 3589. CrossRef